Zhou Feng

United States Food and Drug Administration

Also affiliated with Center for Drug Evaluation and Research

Biochemistry, Genetics and Molecular BiologyMedicinePsychology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer”.

FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1133

N/A

0DataRank · unranked

9 citations

Christy Osgood, Zhou Feng, Erik Bloomquist, Shenghui Tang, C.J. George Chang +8 more

Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer

Bladder Cancer(2023)10.3233/blc-230056

N/A

0DataRank · unranked

8 citations

Noah M. Hahn, Seth P. Lerner, Jaleh Fallah, Sundeep Agrawal, Ashish M. Kamat +33 more